intranasal oxytocin in the treatment of schizophrenia

The effect of intranasal oxytocin on negative symptoms in patients with chronic schizophrenia: a double blind and placebo controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202251556N35

Enrollment

Registered

2012-02-27

Start date

2012-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. schizophrenia

Interventions

Intervention 1: Risperidone combined with placebo for 8 weeks. Intervention 2: Risperidone combined with intranasal oxytocin(titrated to 40IU /twice day) as intervention group for 8 weeks.

Placebo

Treatment - Drugs

Risperidone combined with placebo for 8 weeks

Risperidone combined with intranasal oxytocin(titrated to 40IU /twice day) as intervention group for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 18-50, Diagnosis of Schizophrenia based on DSM IV 3 chronic Schizophrenia( duration of the disorder>2 years), Minimum Score of 60 on Positive and Negative Scale- Exclusion Criteria:1- Substance dependence,2- IQ <70, 3-any other mental disorder on axis I, 4-Any serious medical or neurological problem ,5- receiving ECT during the last 14 days, 6- hepatic disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026